-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SQn8iSCoZTzX1Zk7jQhpoK+j28QgrErubIcIXkg0LMtuBhk/P6LCSA9H5GSlZeny PrI+OKraEj5XDymqQThvzg== 0001104659-04-011433.txt : 20040427 0001104659-04-011433.hdr.sgml : 20040427 20040427172433 ACCESSION NUMBER: 0001104659-04-011433 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040422 ITEM INFORMATION: ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NBTY INC CENTRAL INDEX KEY: 0000070793 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112228617 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31788 FILM NUMBER: 04757836 BUSINESS ADDRESS: STREET 1: 90 ORVILLE DR CITY: BOHEMIA STATE: NY ZIP: 11716 BUSINESS PHONE: 5165679500 MAIL ADDRESS: STREET 1: 90 ORVILLE DRIVE CITY: BOHEMIA STATE: NY ZIP: 11716 FORMER COMPANY: FORMER CONFORMED NAME: NATURES BOUNTY INC DATE OF NAME CHANGE: 19920703 8-K 1 a04-4938_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 22, 2004
 

NBTY, INC.

 (Exact name of registrant as specified in charter)

 

001-31788

(Commission file number)

 

 

 

DELAWARE

 

11-2228617

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

 

90 Orville Drive
Bohemia, New York

 

11716

(Address of principal executive offices)

 

(Zip Code)

 

 

 

(631) 567-9500

(Registrant’s telephone number, including area code)

 

 



 

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

 

(c)                 Exhibits.

 

99.1 Press release issued by NBTY, Inc. dated April 22, 2004

 

ITEM 12.               RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

On April 22, 2004, NBTY, Inc. issued a press release announcing fiscal second quarter results.  A copy of the press release is attached as Exhibit 99.1.

 

This information is furnished under “Item 12. Disclosure of Results of Operations and Financial Condition” in accordance with SEC Release Nos. 33-8216 and 34-47583.

 

This Form 8-K and the attached Exhibit are furnished to comply with Item 7 and Item 12 of Form 8-K.  Neither this Form 8-K nor the attached Exhibit are to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 (except as shall be expressly set forth by specific reference in such filing).

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated:  April 27, 2004

 

 

 

 

 

 

NBTY, INC.

 

 

 

 

 

 

By:

/s/ Harvey Kamil

 

 

 

Harvey Kamil

 

 

President and Chief Financial Officer

 

3


EX-99.1 2 a04-4938_1ex99d1.htm EX-99.1

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Contact: Harvey Kamil

Carl Hymans

 

NBTY, Inc.

G.S. Schwartz & Co.

 

President and

212-725-4500

 

Chief Financial Officer

carlh@schwartz.com

 

631-244-2020

 

 

NBTY REPORTS RECORD SECOND QUARTER RESULTS

 

BOHEMIA, N.Y. – April 22, 2004 - NBTY, Inc. (NYSE: NTY) (www.NBTY.com), a leading manufacturer and marketer of nutritional supplements, today announced record results for the fiscal second quarter ended March 31, 2004.

 

For the fiscal second quarter ended March 31, 2004, sales increased 58% to $440 million, compared to sales of $278 million for the fiscal second quarter ended March 31, 2003.  Net income for the fiscal second quarter was $41 million, or $0.60 per diluted share, compared to net income of  $20 million, or $0.29 per diluted share for the fiscal second quarter last year.   (Without a one-time $6 million discontinued product charge, net income and earnings per diluted share for the fiscal second quarter of 2003 would have been $24 million and $0.34, respectively.)

 

Results for the fiscal second quarter of 2004 reflect increased sales across all the Company’s businesses and include the results of Rexall businesses acquired in July 2003.  Rexall product lines recorded sales of $82 million for the fiscal second quarter.  Without such product lines, sales would have increased 29% for the fiscal second quarter.

 



 

For the first six months of fiscal 2004, sales increased 59% to $825 million, compared to $519 million for the first six months of fiscal 2003.  Net income for the first six months of fiscal 2004 was $65 million, or $0.94 per diluted share, compared with $36 million, or $0.53 per diluted share for the first six months of fiscal 2003.   (Without the aforementioned one-time $6 million charge, net income and earnings per diluted share for the first six months of fiscal 2003 would have been $40 million and $0.59, respectively.)

 

NBTY continues to enhance its financial strength.   During the first six months of fiscal 2004, the Company repaid a total of $98 million of principal outstanding under its term loans; $24 million in the first fiscal quarter ended December 31, 2003 and $74 million in the second fiscal quarter ended March 31, 2004.  These payments reduced the principal amount of outstanding term loans to $174 million from the principal balance of $272 million at September 30, 2003.

 

OPERATIONS FOR THE FISCAL SECOND QUARTER ENDED MARCH 31, 2004

 

The US Nutrition wholesale division, which operates Nature’s Bounty and Rexall, increased its sales 123% to $189 million from $85 million for the comparable prior period of fiscal 2003.  These results include $82 million from Rexall product lines, such as Osteo Bi-Flex®, MET-Rx®, Sundown® and Carb Solutions®, and include a charge of approximately $3 million for returns associated with Rexall’s pre-acquisition sales.  These returns have decreased steadily since the Rexall acquisition in July 2003, as the Company maximizes Rexall retail space and replaces pre-acquisition slower-moving Rexall products with reformulated Rexall products as well as Nature’s Bounty premium products.

 

US Nutrition’s results reflect the continued success of the integration of Rexall and additional growth in mass-market sales.   The Company now employs 575 former Rexall associates, approximately 350 fewer than at the time of the acquisition.

 



 

NBTY continues to increase its dominant presence in the wholesale nutritional supplement marketplace.  The Company’s utilization of consumer sales information, received on a daily basis from its Vitamin World retail stores and Puritan’s Pride direct-response/e-commerce operations, continues to provide mass-market customers with timely and vital data to drive sales.

 

Vitamin World fiscal second quarter sales were $56 million compared to $54 million a year ago, an increase of 5%.  Vitamin World operations generated continued profitability in the fiscal second quarter and EBITDA (as defined in non-GAAP financial measures below) was $4 million. Same store sales increased 4%.  During the fiscal second quarter Vitamin World opened 5 new stores, closed 3 stores and at the end of the quarter operated 545 stores nationwide.

 

NBTY’s European retail sales for the fiscal second quarter increased 42% to $123 million from $87 million for the fiscal second quarter a year ago. This increase includes sales generated by the 50 GNC stores in the UK and 67 DeTuinen stores in the Netherlands that NBTY acquired in fiscal 2003.  GNC (UK) and DeTuinen each generated sales of approximately $10 million for the fiscal second quarter.  While results for the DeTuinen chain, acquired in May 2003, were not profitable, a turn-around is anticipated within the next 12 months based upon the chain’s progress to date.  During the fiscal second quarter, the Company’s European retail division opened 6 new stores, closed 3 stores and at the end of the quarter operated 599 stores in the UK, Ireland and the Netherlands.

 

Holland & Barrett continues to be a leader in the United Kingdom with same store sales increasing 21% for the fiscal second quarter, reflecting in part, the positive effect of the strong British pound.  Without the effect of foreign exchange, Holland & Barrett same store sales increased 6%.

 



 

Revenues from Puritan’s Pride direct response/e-commerce operations for the fiscal second quarter increased 35% to $71 million from $52 million for the comparable prior period. Puritan’s Pride on-line sales increased 58% for the fiscal second quarter and comprised 20% of all direct response sales for this fiscal second quarter.  The increase in sales reflects the Company’s ability to more effectively target market its customer base.  During this fiscal quarter, the Company shipped 63,000 more orders than in the prior like quarter, and average order size increased $14 to $79 from $65.   NBTY remains the leader in the direct response and e-commerce sector and continues to increase the number of products available via its catalog and websites.

 

NBTY Chairman and CEO, Scott Rudolph, said:  “We are very pleased to report a second consecutive quarter of record results and sales increases across all divisions.  The successful integration of Rexall continues to contribute to our overall revenue growth and lends further credence to our strategic plan to enhance wholesale operations and further our position as the dominant force in the worldwide nutritional supplement market.  We anticipate continued growth in revenue and market share and remain confident in the long-term outlook for NBTY.”

 

ABOUT NBTY

NBTY is a leading vertically integrated manufacturer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world.  The Company markets approximately 1,500 products under several brands, including Nature’s Bountyâ, Vitamin Worldâ, Puritan’s Prideâ, Holland & Barrettâ, Rexallâ, Sundownâ, MET-Rx®, WORLDWIDE Sport Nutrition®, American Healthâ, GNC (UK)â and DeTuinen®.

 

This release refers to non-GAAP financial measures, such as EBITDA.  “EBITDA” is defined as earnings before interest, taxes, depreciation and amortization.  This non-GAAP financial measure is not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the non-GAAP measure to the comparable GAAP measure is included in the attached financial tables.  Management believes the presentation of EBITDA is relevant and useful because EBITDA is a measurement industry analysts utilize when evaluating NBTY’s operating performance. Management also believes EBITDA enhances an investor’s understanding of NBTY’s results of operations because it measures NBTY’s operating performance exclusive of interest and non-cash charges for depreciation and amortization. Management also provides this non-GAAP measurement as a way to help investors better understand its core operating performance, enhance comparisons of NBTY’s core operating performance from period to period and to allow better comparisons of NBTY’s operating performance to that of its competitors.

 



 

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. All of these forward-looking statements, which can be identified by the use of terminology such as “subject to,” “believe,” “expects,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy which, although believed to be reasonable, are inherently uncertain.  Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of war, terrorism, bio-terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance; (xiv) exposure to and expense of defending and resolving, product liability claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY’s products; (xviii) the inability of NBTY to renew leases on its retail locations; (xix) inability of NBTY’s retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY’s products; (xxi) sales and earnings volatility and/or trends; (xxii) the efficacy of NBTY’s Internet and on-line sales and marketing; (xxiii) fluctuations in foreign currencies, including the British Pound; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail locations; (xxvi) introduction of new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly the Food Supplements Directive and the Traditional Herbal Medicinal Products Directive in Europe; (xxvii) the mix of NBTY’s products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY’s filings with the U.S. Securities and Exchange Commission; and (xxx) other factors beyond NBTY’s control.

 

Readers are cautioned not to place undue reliance on forward-looking statements.  NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements.  NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

 



 

NBTY, INC. and SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

 

(UNAUDITED)

 

(Dollars and shares in thousands, except per share amounts)

 

 

 

For the three months
ended March 31,

 

 

 

2004

 

2003

 

 

 

 

 

 

 

Net sales

 

$

439,594

 

$

277,824

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

Cost of sales

 

213,248

 

124,679

 

Discontinued product charge

 

 

6,000

 

Catalog printing, postage and promotion

 

19,322

 

16,782

 

Selling, general and administrative

 

138,294

 

99,170

 

 

 

370,864

 

246,631

 

 

 

 

 

 

 

Income from operations

 

68,730

 

31,193

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

Interest

 

(6,759

)

(3,774

)

Miscellaneous, net

 

540

 

2,274

 

 

 

(6,219

)

(1,500

)

 

 

 

 

 

 

Income before income taxes

 

62,511

 

29,693

 

 

 

 

 

 

 

Provision for income taxes

 

21,254

 

10,082

 

 

 

 

 

 

 

Net income

 

$

41,257

 

$

19,611

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

Basic

 

$

0.62

 

$

0.30

 

Diluted

 

$

0.60

 

$

0.29

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

Basic

 

66,730

 

66,261

 

Diluted

 

69,098

 

68,323

 

 



 

 

 

For the six months
ended March 31,

 

 

 

2004

 

2003

 

 

 

 

 

 

 

Net sales

 

$

824,647

 

$

519,228

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

Cost of sales

 

406,134

 

231,359

 

Discontinued product charge

 

 

6,000

 

Catalog printing, postage and promotion

 

39,459

 

30,637

 

Selling, general and administrative

 

268,665

 

192,546

 

 

 

714,258

 

460,542

 

 

 

 

 

 

 

Income from operations

 

110,389

 

58,686

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

Interest

 

(13,564

)

(7,820

)

Miscellaneous, net

 

2,047

 

3,513

 

 

 

(11,517

)

(4,307

)

 

 

 

 

 

 

Income before income taxes

 

98,872

 

54,379

 

 

 

 

 

 

 

Provision for income taxes

 

33,970

 

18,145

 

 

 

 

 

 

 

Net income

 

$

64,902

 

$

36,234

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

Basic

 

$

0.97

 

$

0.55

 

Diluted

 

$

0.94

 

$

0.53

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

Basic

 

66,686

 

66,216

 

Diluted

 

68,997

 

68,205

 

 



 

SALES

(Thousands)

(Unaudited)

 

 

 

THREE MONTHS ENDED
MARCH 31,

 

SIX MONTHS ENDED
MARCH 31,

 

 

 

2004

 

2003

 

% Increase

 

2004

 

2003

 

% Increase

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

$

189,425

 

$

84,850

 

123

%

$

368,620

 

$

158,967

 

132

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

56,100

 

53,556

 

5

%

109,511

 

103,819

 

5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

UK Retail /
Holland & Barrett / GNC

 

123,416

 

87,089

 

42

%

240,466

 

169,702

 

42

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Direct Response /
Puritan’s Pride

 

70,653

 

52,329

 

35

%

106,050

 

86,740

 

22

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$

439,594

 

$

277,824

 

58

%

$

824,647

 

$

519,228

 

59

%

 

GROSS PROFIT

PERCENTAGES

(Unaudited)

 

 

 

THREE MONTHS ENDED
MARCH 31,

 

SIX MONTHS ENDED
MARCH 31,

 

 

 

2004

 

2003

 

% Increase
(% Decrease)

 

2004

 

2003

 

%Increase
(% Decrease)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

39

%

41

%

-2

%

38

%

42

%

-4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

60

%

59

%

1

%

60

%

59

%

1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

European Retail /
Holland & Barrett / GNC

 

62

%

63

%

-1

%

61

%

63

%

-2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Direct Response /
Puritan’s Pride

 

61

%

61

%

0

%

61

%

62

%

-1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total (without discontinued product charge)

 

52

%

55

%

-3

%

51

%

55

%

-4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discontinued product charge

 

0

%

-2

%

2

%

0

%

-1

%

1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

52

%

53

%

-1

%

51

%

54

%

-3

%

 



 

Reconciliation of GAAP Measures to Non-GAAP Measures

(Thousands)

(Unaudited)

 

 

 

THREE MONTHS ENDED

MARCH 31, 2004

 

 

 

Pretax Income
(Loss)

 

Depreciation and
amortization

 

Interest

 

EBITDA

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

$

40,999

 

$

2,764

 

$

 

$

43,763

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

1,193

 

3,027

 

 

 

4,220

 

 

 

 

 

 

 

 

 

 

 

European Retail /
Holland & Barrett / GNC

 

29,683

 

3,394

 

 

 

33,077

 

 

 

 

 

 

 

 

 

 

 

Direct Response / Puritan’s Pride

 

23,418

 

1,393

 

 

 

24,811

 

 

 

 

 

 

 

 

 

 

 

Segment Results

 

95,293

 

10,578

 

 

 

105,871

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

(32,782

)

5,501

 

6,759

 

(20,522

)

 

 

 

 

 

 

 

 

 

 

Total

 

$

62,511

 

$

16,079

 

$

6,759

 

$

85,349

 

 

 

 

 

THREE MONTHS ENDED

MARCH 31, 2003

 

 

 

Pretax Income
(Loss)

 

Depreciation and
amortization

 

Interest

 

EBITDA

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

$

17,950

 

$

242

 

$

 

$

18,192

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

1,093

 

3,000

 

 

 

4,093

 

 

 

 

 

 

 

 

 

 

 

European Retail /
Holland & Barrett / GNC

 

23,069

 

2,373

 

 

 

25,442

 

 

 

 

 

 

 

 

 

 

 

Direct Response / Puritan’s Pride

 

13,958

 

1,601

 

 

 

15,559

 

 

 

 

 

 

 

 

 

 

 

Segment Results

 

56,070

 

7,216

 

 

 

63,286

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

(26,377

)

3,981

 

3,774

 

(18,622

)

 

 

 

 

 

 

 

 

 

 

Total

 

$

29,693

 

$

11,197

 

$

3,774

 

$

44,664

 

 



 

 

 

 

SIX MONTHS ENDED
MARCH 31, 2004

 

 

 

Pretax Income
(Loss)

 

Depreciation and
amortization

 

Interest

 

EBITDA

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

$

71,007

 

$

5,442

 

$

 

$

76,449

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

1,389

 

6,186

 

 

 

7,575

 

 

 

 

 

 

 

 

 

 

 

European Retail /
Holland & Barrett / GNC

 

55,982

 

5,900

 

 

 

61,882

 

 

 

 

 

 

 

 

 

 

 

Direct Response / Puritan’s Pride

 

32,686

 

2,808

 

 

 

35,494

 

 

 

 

 

 

 

 

 

 

 

Segment Results

 

161,064

 

20,336

 

 

 

181,400

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

(62,192

)

10,922

 

13,564

 

(37,706

)

 

 

 

 

 

 

 

 

 

 

Total

 

$

98,872

 

$

31,258

 

$

13,564

 

$

143,694

 

 

 

 

 

SIX MONTHS ENDED
MARCH 31, 2003

 

 

 

Pretax Income
(Loss)

 

Depreciation and
amortization

 

Interest

 

EBITDA

 

 

 

 

 

 

 

 

 

 

 

Wholesale

 

$

32,154

 

$

452

 

$

 

$

32,606

 

 

 

 

 

 

 

 

 

 

 

US Retail / Vitamin World

 

(562

)

5,936

 

 

 

5,374

 

 

 

 

 

 

 

 

 

 

 

European Retail /
Holland & Barrett / GNC

 

45,361

 

4,538

 

 

 

49,899

 

 

 

 

 

 

 

 

 

 

 

Direct Response / Puritan’s Pride

 

24,972

 

2,938

 

 

 

27,910

 

 

 

 

 

 

 

 

 

 

 

Segment Results

 

101,925

 

13,864

 

 

 

115,789

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

(47,546

)

7,888

 

7,820

 

(31,838

)

 

 

 

 

 

 

 

 

 

 

Total

 

$

54,379

 

$

21,752

 

$

7,820

 

$

83,951

 

 



 

NBTY, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

ASSETS

 

(Dollars and shares in thousands)

 

 

 

March 31,
2004

 

September 30,
2003

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

54,709

 

$

49,349

 

Investments in bonds

 

 

4,158

 

Accounts receivable, less allowance for doubtful accounts of $8,077 at March 31, 2004 and $7,100 at September 30, 2003

 

93,128

 

80,829

 

 

 

 

 

 

 

Inventories

 

308,610

 

314,091

 

 

 

 

 

 

 

Deferred income taxes

 

37,021

 

37,021

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

31,902

 

44,736

 

 

 

 

 

 

 

Total current assets

 

525,370

 

530,184

 

 

 

 

 

 

 

Property, plant and equipment, net

 

298,806

 

298, 344

 

 

 

 

 

 

 

Goodwill

 

212,722

 

213,362

 

 

 

 

 

 

 

Intangible assets, net

 

141,489

 

137,469

 

 

 

 

 

 

 

Other assets

 

17,631

 

16,423

 

 

 

 

 

 

 

Total assets

 

$

1,196,018

 

$

1,195,782

 

 



 

NBTY, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

(Dollars and shares in thousands)

 

 

 

March 31,
2004

 

September 30,
2003

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Current portion of long-term debt and capital lease obligations

 

$

2,834

 

$

12,841

 

Accounts payable

 

87,412

 

87,039

 

Accrued expenses and other current liabilities

 

124,994

 

116,029

 

Total current liabilities

 

215,240

 

215,909

 

 

 

 

 

 

 

Long-term debt

 

326,030

 

413,989

 

Deferred income taxes

 

40,005

 

40,213

 

Other liabilities

 

5,391

 

10,872

 

Total liabilities

 

586,666

 

680,983

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Common stock, $0.008 par; authorized 175,000 shares; issued and outstanding 66,735 shares at March 31, 2004 and 66,620 shares at September 30, 2003

 

534

 

533

 

 

 

 

 

 

 

Capital in excess of par

 

132,900

 

130,208

 

Retained earnings

 

434,355

 

369,453

 

 

 

567,789

 

500,194

 

 

 

 

 

 

 

Accumulated other comprehensive income

 

41,563

 

14,605

 

Total stockholders’ equity

 

609,352

 

514,799

 

 

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

1,196,018

 

$

1,195,782

 

 



 

NBTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

 

For the six months ended
March 31,

 

(Dollars in thousands)

 

2004

 

2003

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

64,902

 

36,234

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Loss/(Gain) on sale/disposal of property, plant and equipment

 

492

 

(962

)

Depreciation and amortization

 

31,258

 

21,752

 

Foreign currency exchange rate gain

 

(240

)

(906

)

Amortization of deferred financing costs

 

1,812

 

394

 

Amortization of bond discount

 

62

 

62

 

Allowance for doubtful accounts

 

977

 

98

 

Compensation expense for ESOP

 

2,473

 

855

 

Tax benefit from exercise of stock options

 

132

 

113

 

Changes in assets and liabilities:

 

 

 

 

 

Accounts receivable

 

(12,417

)

(4,436

)

Inventories

 

9,905

 

(6,877

)

Prepaid expenses and other current assets

 

16,444

 

(7,251

)

Other assets

 

367

 

59

 

Accounts payable

 

(3,597

)

7,426

 

Accrued expenses and other liabilities

 

1,286

 

120

 

Net cash provided by operating activities

 

113,856

 

46,681

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Purchase of property, plant and equipment

 

(21,916

)

(17,686

)

Proceeds from sale of property, plant, and equipment

 

83

 

1,293

 

Proceeds from sale of investment in bonds

 

4,158

 

 

Cash paid for acquisitions, net of cash acquired

 

 

(14,786

)

Release of cash held in escrow

 

 

2,403

 

 

 

 

 

 

 

Net cash used in investing activities

 

(17,675

)

(28,776

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Principal payments under long-term debt agreements and capital leases

 

(98,027

)

(11,616

)

Payments for debt issuance costs

 

(500

)

 

Proceeds from stock options exercised

 

88

 

176

 

 

 

 

 

 

 

Net cash used in financing activities

 

(98,439

)

(11,440

)

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

7,618

 

1,080

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

5,360

 

7,545

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

49,349

 

26,229

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

54,709

 

33,774

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

Cash paid during the period for interest

 

$

11,798

 

$

8,218

 

Cash paid during the period for income taxes

 

$

16,780

 

$

15,480

 

 


-----END PRIVACY-ENHANCED MESSAGE-----